NeurologyLive® Year in Review 2024: Most-Watched Expert Interviews

Throughout the course of the year, the NeurologyLive^® team spoke with experts across the breadth of neurology about the topics and themes that have driven the conversations in the field in 2024. In total, our team spent thousands of hours speaking with hundreds of individuals who are driving the medical science being done to help patients with chronic conditions.

Among those conversations included discussions about new updates to treatment guidelines in multiple sclerosis and restless legs syndrome, conversations around the neurologic implications of long COVID infection, and various updates on novel and exciting therapeutic approaches to conditions such as muscular dystrophy, intracranial hemorrhage, and cervical dystonia, among others.

Here, we'll highlight the most-watched clips on NeurologyLive^® this year. Click the buttons to read further into these conversations.

1. 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

The codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]

2. New Treatment Guidelines for Restless Legs Syndrome and Shifting Away From Dopamine Agonists: John Winkelman, MD, PhD

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital talked about the new clinical guidelines for treating restless legs syndrome which emphasize the risks of dopamine agonists and advocate for alternative therapies. [WATCH TIME: 8 minutes]

3. Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN

The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]

4. The Evolving Landscape of Treatments for Multiple Sclerosis in 2024: Enrique Alvarez, MD, PhD

The associate professor of neurology at the University of Colorado School of Medicine talked about promising developments in multiple sclerosis treatment strategies for 2024. [WATCH TIME: 6 minutes]

5. Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

6. Introducing DaxibotulinumtoxinA-Ianm as a Treatment Option for Cervical Dystonia: Peter J. McAllister, MD, FAAN

The chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]

7. Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko

The chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]

8. A Dive Into the Neurological Impact of Long COVID and Hyperbaric Oxygen Therapy: Amir Hadanny, MD, PhD

The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]

9. Promising Developments in Pharmaceutical Treatments for Sleep Apnea: Sanjay R. Patel, MD, MS

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]

10. Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhD

The president and CEO at Alzheon talked about the recent discoveries made in understanding the pathology of Alzheimer disease and the development of innovative therapies to potentially set the stage for more effective care. [WATCH TIME: 12 minutes]